Investigation of serum psa in men above 45 years old with lower urinary tract symptoms
Main Article Content
Abstract
PSA is a unique antigen of the prostate. However, PSA is not specific for prostate cancer. Hence, it is important to determine the distribution of nomal PSA level. There is a lack of studies on PSA level of Vietnamese men and the initial database of PSA profile of Vietnamese men for future research is insufficient. For these reasons, we conducted a study on serum PSA level in men above 45 years old with lower urinary tract symptoms at Hanoi Medical University Hospital to investigate the relationship between PSA level and clinical and subclinical characteristics. Our results showed that the mean level of PSA was 1.85 ng/ml with the majority of patients had the PSA level below 4 ng/ml. The level of PSA elevated in accordance with an increase in age, prostate volume and with the presence of voiding symptoms. There was a correlation between age, prostate volume and PSA level. For each year increase in age and each 1 ml increase in prostate volume would result in 0.09 ng/ml and 0.11 ng/ml elevation of PSA concentration, respectively. In conclusion, in clinical practice, the individualization of PSA level requires the assessment of voiding symptoms, age and prostate volume.
Article Details
Keywords
PSA, lower urinary tract symptoms, benign prostate hyperplasia
References
2. Hugosson J, Roobol MJ, Månsson M, et al. A 16 - yr Follow - up of the European Randomized study of Screening for Prostate Cancer. Eur Urol. 2019;76(1):43 - 51. doi:10.1016/j.eururo.2019.02.009
3. Carlsson S, Assel M, Ulmert D, et al. Screening for Prostate Cancer Starting at Age 50–54 Years. A Population - based Cohort Study. European Urology. 2017;71(1):46 - 52. doi:10.1016/j.eururo.2016.03.026
4. Albertsen PC. The Unintended Burden of Increased Prostate Cancer Detection Associated With Prostate Cancer Screening and Diagnosis. Urology. 2010;75(2):399 - 405. doi:10.1016/j.urology.2009.08.078
5. Van Dong H, Lee AH, Nga NH, Quang N, Le Chuyen V, Binns CW. Epidemiology and prevention of prostate cancer in Vietnam. Asian Pac J Cancer Prev. 2014;15(22):9747 - 9751. doi:10.7314/apjcp.2014.15.22.9747
6. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub - committee of the International Continence Society. Urology. 2003;61(1):37 - 49. doi:10.1016/s0090 - 4295(02)02243 - 4
7. Yoon H. Metabolic Syndrome and Lower Urinary Tract Symptoms: Epidemiological Study. LUTS: Lower Urinary Tract Symptoms. 2012;4(s1):2 - 7. doi:10.1111/j.1757 - 5672.2011.00119.x
8. De Nunzio C, Lombardo R, Tema G, Tubaro A. Erectile Dysfunction and Lower Urinary Tract Symptoms. Curr Urol Rep. 2018;19(8):61. doi:10.1007/s11934 - 018 - 0817 - 9
9. Park JS, Koo KC, Kim HK, Chung BH, Lee KS. Impact of metabolic syndrome - related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population. Medicine (Baltimore). 2019;98(42):e17635. doi:10.1097/MD.0000000000017635
10. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non - neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099 - 1109. doi:10.1016/j.eururo.2014.12.038
11. Schröder FH, Carter HB, Wolters T, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol. 2008;53(3):468 - 477. doi:10.1016/j.eururo.2007.10.047
12. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate - specific antigen and prostate volume predict long - term changes in symptoms and flow rate: results of a four - year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999;54(4):662 - 669. doi:10.1016/s0090 - 4295(99)00232 - 0
13. Patel DN, Feng T, Simon RM, et al. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018;21(2):238 - 244. doi:10.1038/s41391 - 018 - 0044 - y
14. Harrison S, Tilling K, Turner EL, et al. Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI - adjusted PSA model clinically useful? Cancer Causes Control. 2016;27(12):1465 - 1474. doi:10.1007/s10552 - 016 - 0827 - 1
15. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long - term efficacy and safety study. J Urol. 2000;163(1):13 - 20.
16. Bohnen AM, Groeneveld FP, Bosch JLHR. Serum Prostate - Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study. European Urology. 2007;51(6):1645 - 1653. doi:10.1016/j.eururo.2007.01.084